案例报告:在ERBB2增强的宫粘膜黑色素瘤中,trastuzumab deruxtecan加上toripalimab
Xiao-Xia Wang1, Min-Xin Wang2, Chao Sui1
1Department of Oncology, Weihai Central Hospital Affiliated to Qingdao University, Weihai, Shandong, China.
Frontiers in oncology
|September 19, 2025
概括
一种罕见的HER2阳性宫黑色素瘤在新型组合疗法下显示出显著的瘤缩. 这种使用trastuzumab deruxtecan (T-DXd) 和toripalimab的方法为这种攻击性癌症提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 免疫治疗是一种免疫疗法.
背景情况:
- 宫粘膜黑色素瘤是一种罕见的,具有不良结果的侵袭性癌症.
- 目前的化疗和免疫疗法等治疗方法的疗效有限,抗药率高.
研究的目的:
- 报告首次成功治疗HER2阳性宫粘膜黑色素瘤,使用新型组合疗法.
- 为了评估trastuzumab deruxtecan (T-DXd) 与Toripalimab结合的安全性和疗效.
主要方法:
- 一名患有HER2阳性宫粘膜黑色素瘤的患者的病例报告.
- 使用特鲁苏马布德鲁克斯坦 (T-DXd) 和托里帕利马布的治疗.
主要成果:
- 实现了显著的瘤缩,表明部分反应.
- 证明了组合治疗的良好的安全性.
结论:
- 结合T-DXd和Toripalimab对HER2阳性宫粘膜黑色素瘤的治疗有希望.
- 这一策略突出了抗体-药物联合体 (ADC) 和免疫向协同作用在治疗耐火性粘膜黑色素瘤中的潜力.
- 需要进一步的临床试验来验证这种治疗方法.
相关概念视频
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K